DDInter257 DDInter899
Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervous system (CNS) depression that ranges from mild sedation to general anesthesia. Butalbital has a low degree of selectivity and a narrow therapeutic index. Typically indicated to manage tension (or muscle contraction) headaches, butalbital is often combined with one or more therapeutic agents, such as acetylsalicylic acid, acetaminophen, aspirin, and caffeine. There have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines thus it is not indicated for such condition. As with other barbiturates
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Butalbital {u} (Compound) resembles {v} (Compound) Aprobarbital
Butalbital {u} (Compound) resembles {v} (Compound) Secobarbital
Butalbital {u} (Compound) binds {v} (Gene) CHRNA4
Butalbital {u} (Compound) palliates {v} (Disease) migraine
Butalbital {u} (Compound) is included by {v} (Pharmacologic Class) Barbiturates
Butalbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Butalbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Butalbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ribociclib
Butalbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calcifediol
Butalbital {u} may lead to a major life threatening interaction when taken with {v} Hemin
Butalbital (Compound) resembles Aprobarbital (Compound)
Butalbital (Compound) resembles Secobarbital (Compound)
Butalbital (Compound) binds CHRNA4 (Gene)
Butalbital (Compound) palliates migraine (Disease)
Butalbital (Compound) is included by Barbiturates (Pharmacologic Class)
Butalbital may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Butalbital may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Calcifediol
Butalbital may lead to a major life threatening interaction when taken with Hemin